This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
European Association of Nuclear Medicine (EANM) 2024
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Video Lectures
Treatments in Development in NMIBC Videos
MoonRISe-1: Evaluating TAR-210 for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer - Roger Li
June 19, 2024
Details
Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li
June 12, 2024
Details
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
June 6, 2024
Details
AI-Based Assessment Tool for Predicting BCG Response in Bladder Cancer Patients - Yair Lotan
May 14, 2024
Details
Leveraging AI Biomarkers to Navigate the Evolving Landscape of Bladder Cancer Treatment - Stephen Williams
May 15, 2024
Details
PIVOT-006: Phase 3 Trial Comparing Oncolytic Virus Creto vs Observation for Intermediate-Risk NMIBC - Robert Svatek
May 13, 2024
Details
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson
May 10, 2024
Details
Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson
May 3, 2024
Details
Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua
March 12, 2024
Details
Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram
March 12, 2024
Details
PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson
February 13, 2024
Details
BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson
January 8, 2024
Details
Cretostimogene Grenadenorepvec Therapy Aims to Fill an Unmet Need in the Bladder Cancer Armamentarium - Robert Svatek
December 12, 2023
Details
Combining CG0070 Adenovirus Vector with Immune Checkpoint Blockade: Promising Results for BCG Unresponsive Bladder Cancer Patients - Roger Li
March 29, 2023
Details
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
